187 related articles for article (PubMed ID: 20103744)
1. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.
Hare KJ; Vilsbøll T; Holst JJ; Knop FK
Am J Physiol Endocrinol Metab; 2010 Apr; 298(4):E832-7. PubMed ID: 20103744
[TBL] [Abstract][Full Text] [Related]
2. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
[TBL] [Abstract][Full Text] [Related]
3. On the role of the gut in diabetic hyperglucagonaemia.
Lund A
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
[TBL] [Abstract][Full Text] [Related]
4. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare KJ
Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
[TBL] [Abstract][Full Text] [Related]
5. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
6. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
[TBL] [Abstract][Full Text] [Related]
7. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
8. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2010 Jul; 95(7):3309-17. PubMed ID: 20410219
[TBL] [Abstract][Full Text] [Related]
9. Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion.
Lund A; Bagger JI; Christensen M; Grøndahl M; van Hall G; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2016 Nov; 101(11):4377-4384. PubMed ID: 27533305
[TBL] [Abstract][Full Text] [Related]
10. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
11. C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test.
Iwasaki Y; Kondo K; Hasegawa H; Oiso Y
Diabetes Res; 1994; 25(3):129-37. PubMed ID: 7671552
[TBL] [Abstract][Full Text] [Related]
12. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T
Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937
[TBL] [Abstract][Full Text] [Related]
13. Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance.
Muscelli E; Mari A; Natali A; Astiarraga BD; Camastra S; Frascerra S; Holst JJ; Ferrannini E
Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1144-50. PubMed ID: 16478775
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
[TBL] [Abstract][Full Text] [Related]
15. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
Lugari R; Dell'Anna C; Ugolotti D; Dei Cas A; Barilli AL; Zandomeneghi R; Marani B; Iotti M; Orlandini A; Gnudi A
Horm Metab Res; 2000 Oct; 32(10):424-8. PubMed ID: 11069208
[TBL] [Abstract][Full Text] [Related]
16. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
[TBL] [Abstract][Full Text] [Related]
17. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
[TBL] [Abstract][Full Text] [Related]
18. The role of diminished beta cell reserve and insulin resistance in secondary sulfonylurea failure of type 2 diabetes mellitus.
Rattarasarn C; Thamprasit A; Leelawattana R; Soonthornpun S; Setasuban W
J Med Assoc Thai; 2001 Dec; 84(12):1754-62. PubMed ID: 11999824
[TBL] [Abstract][Full Text] [Related]
19. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
20. Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes.
Forbes S; Moonan M; Robinson S; Anyaoku V; Patterson M; Murphy KG; Ghatei MA; Bloom SR; Johnston DG
Clin Endocrinol (Oxf); 2005 Jan; 62(1):51-5. PubMed ID: 15638870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
